At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
In Brief
A Phase 4 clinical trial evaluating Doxorubicin and Cyclophosphamide for Breast Cancer and Obesity. Completed, enrolled 15 participants across 1 site.
Detailed Summary
To determine the effect of weight on doxorubicin and cyclophosphamide plasma clearance in participants who are normal weight (body mass index \[BMI\] \< 25 kg/m2, overweight or class I obese (BMI 25-34.9 kg/m2), or class II-III obese (BMI ≥ 35 kg/m2). The hypothesis is that participants who weigh more will have higher doxorubicin and cyclophosphamide clearances than participants who weigh less. Restated, the area under the drug-concentration time profile, also known as the AUC, in participants will decrease as participant weight increases.
Study Details
Timeline
Interventions
Dosed by the patient's treating physician according to local standard of care.
dosage form: IV, Dosage, frequency, and duration: According to local standard of care